Overview

Residual Effects of Zolpidem Tartrate Extended Release and Eszopiclone Vs Placebo

Status:
Completed
Trial end date:
2006-04-01
Target enrollment:
Participant gender:
Summary
Investigation of Psychomotor and Cognitive Residual Effects of Single Oral Doses of Zolpidem Tartrate Extended Release 12.5 mg and Eszopiclone 3 mg Compared to Placebo in Healthy Young Volunteers, Using Flurazepam 30 mg as an External Comparator
Phase:
Phase 4
Details
Lead Sponsor:
Sanofi
Treatments:
Zolpidem